dm+d

39045411000001102

New Medicines

Myopridin Central and peripheral muscle spasms (lumbar pain, torticollis, general muscle pain) in adults

Information

Myopridin
New molecular entity
Mibe Pharma UK Ltd

Development and Regulatory status

Launched
None
None
January 2021
Jan 21Available in the UK. 3mg scored tab, 20=£5.36; 100=£26.16 [3].
May 20Approved by the MHRA - the full indication is central and peripheral muscle spasms: lumbar pain, torticollis, general muscle pain, in adults [1].

Category

A centrally acting muscle relaxant. Its pharmacological effect develops via an atropine-like mechanism that acts on both smooth and the striated muscles [1].
Neck pain is one of the most common musculoskeletal complaints. About two thirds of the population will experience neck pain at some point in their lives. Women are affected almost twice as much as men. Prevalence rises with age for men and women and is the highest in the age group between 50-59 years. The percentage of people in whom neck pain becomes chronic is generally thought to be about 10% [2].
Central and peripheral muscle spasms (lumbar pain, torticollis, general muscle pain) in adults
Oral

Evidence based evaluations

SPC